James H. Mathews

Centers for Disease Control and Prevention

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

John T. Roehrig

Centers for Disease Control and Prevention

Robert A. Zimmerman

Hospital of the University of Pennsylvania

Prentice M. Thomas

Dennis W. Trent

The University of Texas Medical Branch at Galveston

L. Janice Campbell

Richard M. Kinney

John Brown University

James R. Morehead

New York University Press

Ann R. Hunt

Colorado State University

Alan D.T. Barrett

The University of Texas Medical Branch at Galveston

John R. Brubaker

Centers for Disease Control and Prevention

Cooperative Institutions

Centers for Disease Control and Prevention

United States Department of Health and Human Services

National Center for Infectious Diseases

The University of Texas Medical Branch at Galveston

Colorado State University

University of Surrey

National Institute for Biological Standards and Control

National Institute of Allergy and Infectious Diseases

Albert Einstein College of Medicine

National Institutes of Health

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Serum dilution neutralization test for California group virus identification and serology

Journal of Clinical Microbiology (1976)

Helen S. Lindsey C. H. Calisher James H. Mathews

The serum dilution neutralization test was evaluated for serological diagnosis of California group arbovirus infections and identification of virus isolates. The technical advantages and the degree of subtype specificity of the serum dilution neutralization test over the hemagglutination inhibition test and the complement fixation test were demonstrated with paired specimens from human cases, single human survey sera, and sentinel rabbit sera. Twenty-one virus isolates from various geographical areas of the United States were also used to evaluate the efficacy of the serum dilution neutralization test for specific virus identification.

Complement fixation test

10.1128/jcm.4.6.503-510.1976

Cite

Citations (238)

Fort Polk-3: the Results of a Third Program of Site Testing at Ten Sites Fort Polk Military Reservation Natchitoches Parish, Louisiana

Prentice M. Thomas Joseph B. Meyer James R. Morehead L. Janice Campbell James H. Mathews

POLK

Source

Cite

Citations (0)

Cultural Resources Survey and Site Testing Along the Proposed Transcontinental Gas Pipe Line Corporation (TRANSCO) Woodbury Lateral Natural Gas Pipeline Expansion (Loop D), Gloucester County, New Jersey

James H. Mathews Maria Elana Galdeano J. Brett Cruse

Gas Pipeline

Corporation

Source

Cite

Citations (0)

Molecular and biological characterization of a non-glycosylated isolate of St Louis encephalitis virus

Journal of General Virology (1993)

V. Vorndam James H. Mathews Alan D.T. Barrett John T. Roehrig Dennis W. Trent

The glycosylation patterns of the envelope (E) glycoprotein of several naturally occurring strains of St Louis encephalitis (SLE) virus were investigated. SLE viruses were found that contained both glycosylated and non-glycosylated E proteins, and one isolate (Tr 9464) that lacks N-linked glycosylation sites on its E protein was identified. SLE virus monoclonal antibodies that define E protein B cell epitopes and demonstrate biological activities reacted essentially to the same extent with glycosylated and non-glycosylated virions. These results indicate that glycosylation is not essential for epitope conformation or recognition. However, failure to glycosylate the E protein was associated with possible morphogenetic differences as manifested by reduced virus yields and differences in specific infectivity.

Infectivity

10.1099/0022-1317-74-12-2653

Cite

Citations (40)

Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge

Journal of Virology (1988)

Richard M. Kinney J J Esposito James H. Mathews Barbara J. Johnson John T. Roehrig

Mice immunized with recombinant vaccinia virus (VACC) expressing Venezuelan equine encephalitis (VEE) virus capsid protein and glycoproteins E1 and E2 or with attenuated VEE TC-83 virus vaccine developed VEE-specific neutralizing antibody and survived intraperitoneal challenge with virulent VEE virus strains including Trinidad donkey (subtype 1AB), P676 (subtype 1C), 3880 (subtype 1D), and Everglades (subtype 2). However, unlike immunization with TC-83 virus, immunization with the recombinant VACC/VEE virus did not protect mice from intranasal challenge with VEE Trinidad donkey virus. These results suggest that recombinant VACC/VEE virus is a vaccine candidate for equines and humans at risk of mosquito-transmitted VEE disease but not for laboratory workers at risk of accidental exposure to aerosol infection with VEE virus.

Poxviridae

Orthopoxvirus

Recombinant virus

Attenuated vaccine

10.1128/jvi.62.12.4697-4702.1988

Cite

Citations (47)

Identification of Monoclonal Antibodies that Distinguish Between 17D-204 and other Strains of Yellow Fever Virus

Journal of General Virology (1990)

Alan D.T. Barrett James H. Mathews Barry R. Miller A.R. Medlen T.N. Ledger

Eight monoclonal antibodies (MAbs) prepared against the flaviviruses Saint Louis encephalitis, dengue 2 and dengue 3 viruses all recognized epitopes on the envelope protein of the prototype flavivirus, yellow fever (YF) virus. Three of these MAbs with flavivirus group-common specificity and two MAbs with a flavivirus-subgroup specificity were found to distinguish wild-type YF viruses from YF 17D-204 vaccine virus, but not from the closely related 17DD vaccine virus, nor from the French neurotropic vaccine virus. This pattern of reactivity was seen only with viruses grown in Aedes albopictus C6/36 cells and not with viruses grown in vertebrate cells (SW13 and Vero cells), where all five MAbs recognized epitopes on both wild-type and 17D-204 viruses. Examination of adult A. aegypti mosquitoes infected with the same YF viruses as above gave a different pattern of results to those in C6/36 cells. Thus, epitope expression differs between mammalian and arthropod cells and between arthropod cells in vitro and in vivo. Neutralization tests showed that all five MAbs would neutralize wild-type Asibi virus grown in SW13 cells, but not Asibi virus grown in C6/36 cells, nor 17D-204 vaccine virus grown in either cell type. Therefore, it is concluded that when YF virus is grown in mosquito cells, wild-type virus is antigenically and biologically distinct from the 17D- 204 vaccine virus.

Flavivirus

Vero cell

10.1099/0022-1317-71-1-13

Cite

Citations (25)

T-Helper Cell Epitopes on the E-Glycoprotein of Dengue 2 Jamaica Virus

Virology (1994)

John T. Roehrig Peggy Risi John R. Brubaker Ann R. Hunt Barry J. Beaty

10.1006/viro.1994.1005

Cite

Citations (57)

Data Recovery at 8OK877 at the Kelly Trust Property Phase I Development